NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free INDP Stock Alerts $2.15 +0.06 (+2.87%) (As of 05/10/2024 06:55 PM ET) Add Compare Share Share Today's Range$2.11▼$2.1950-Day Range$1.87▼$2.7752-Week Range$1.56▼$4.08Volume5,400 shsAverage Volume62,542 shsMarket Capitalization$18.36 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Indaptus Therapeutics alerts: Email Address Indaptus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside458.1% Upside$12.00 Price TargetShort InterestHealthy0.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.19Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.83) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.17 out of 5 starsMedical Sector356th out of 925 stocksPharmaceutical Preparations Industry161st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.44% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 70.07%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDP. Previous Next 2.9 News and Social Media Coverage News SentimentIndaptus Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Indaptus Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders27.10% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Indaptus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About Indaptus Therapeutics Stock (NASDAQ:INDP)Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Read More INDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDP Stock News HeadlinesMay 9, 2024 | americanbankingnews.comIndaptus Therapeutics (NASDAQ:INDP) Trading 1.5% Higher May 8, 2024 | investorplace.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.May 8, 2024 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 12, 2024 | investing.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | markets.businessinsider.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingMay 13, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.March 28, 2024 | msn.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingMarch 18, 2024 | finance.yahoo.comIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024March 13, 2024 | msn.comIndaptus Dives on Quarterly ResultsMarch 13, 2024 | benzinga.comIndaptus Therapeutics: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 4, 2024 | markets.businessinsider.comIndaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-marketMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortFebruary 25, 2024 | benzinga.comIndaptus Therapeutics Stock (NASDAQ:INDP) Insider TradesFebruary 15, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comIndaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsJanuary 4, 2024 | finance.yahoo.comEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyDecember 22, 2023 | finance.yahoo.comIndaptus Therapeutics, Inc. (INDP) stock forecast and price targetNovember 27, 2023 | msn.comIndaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20November 7, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Ventyx Biosciences (VTYX) and Indaptus Therapeutics (INDP)November 6, 2023 | msn.comIndaptus Therapeutics GAAP EPS of -$0.47 beats by $0.05See More Headlines Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today5/12/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDP CUSIPN/A CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+458.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.14% Return on Assets-92.86% Debt Debt-to-Equity RatioN/A Current Ratio6.70 Quick Ratio5.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book1.95Miscellaneous Outstanding Shares8,540,000Free Float6,225,000Market Cap$18.36 million OptionableNot Optionable Beta1.28 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Jeffrey A. Meckler (Age 57)CEO & Director Comp: $888.32kMr. Walt Addison Linscott Esq. (Age 63)Chief Operating Officer Comp: $666.63kDr. Michael J. Newman Ph.D. (Age 67)Founder, Chief Scientific Officer & Director Comp: $468.82kMr. Nir Sassi (Age 48)CFO, Secretary & Treasurer Comp: $378.47kDr. Roger J. Waltzman M.B.A. (Age 55)M.D., Chief Medical Officer Key CompetitorsVincerx PharmaNASDAQ:VINCMinerva NeurosciencesNASDAQ:NERVNeuroSense TherapeuticsNASDAQ:NRSNVBI VaccinesNASDAQ:VBIVAytu BioPharmaNASDAQ:AYTUView All CompetitorsInsidersGlen R AndersonBought 23,934 shares on 8/14/2023Total: $56,005.56 ($2.34/share)Glen R AndersonBought 44,354 shares on 8/10/2023Total: $86,046.76 ($1.94/share)View All Insider Transactions INDP Stock Analysis - Frequently Asked Questions Should I buy or sell Indaptus Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDP shares. View INDP analyst ratings or view top-rated stocks. What is Indaptus Therapeutics' stock price target for 2024? 1 brokerages have issued 1-year price objectives for Indaptus Therapeutics' shares. Their INDP share price targets range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 458.1% from the stock's current price. View analysts price targets for INDP or view top-rated stocks among Wall Street analysts. How have INDP shares performed in 2024? Indaptus Therapeutics' stock was trading at $1.76 at the start of the year. Since then, INDP stock has increased by 22.2% and is now trading at $2.15. View the best growth stocks for 2024 here. When is Indaptus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our INDP earnings forecast. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) issued its quarterly earnings results on Wednesday, March, 13th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDP) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupBill Clinton Backing Biden Replacement???The Freeport SocietyDoes this make you sick?Allegiance GoldThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTrump is sounding the alarmPreserve GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
